CHANGES IN THE LIPID PROFILE OF ANIMALS WITH SIMULATED METABOLIC SYNDROME
DOI:
https://doi.org/10.11603/mcch.2410-681X.2021.i4.12731Keywords:
lipoproteins, triglycerides, lipid profile, metabolic syndromeAbstract
Introduction. The formation of atherogenic changes in the lipid profile of metabolic syndrome (MS) is due to the action of many risk factors. Atherogenic dyslipoproteinemia is not only a risk factor for the development and progression of atherosclerosis, but also one of the main components of MS.
The aim of study – to evaluate changes in the lipid profile of rats with simulated MS.
Research Methods. The study was performed on 40 white male Wistar rats weighing 200–250 g. The control group included 8 animals. Male rats of the main group (n=32) were fed a diet high in fat (over 60 % energy from fat) for 16 weeks, thus modeling their development MS. Animals were removed from the experiment by decapitation. The lipid profile in the serum of rats was evaluated using a biochemical analyzer HTI BioChem SA (USA) and standard test kits.
Results and Discussion. It was found that against the background of MS, the rats of the main group compared with controls developed hypercholesterolemia, which was characterized by an increase in animal blood levels of total cholesterol (TC) by 18.38 %, triglycerides (TG) by 77.35 %, low-density lipoprotein (LDL) by 156.52 % with a simultaneous decrease in high-density lipoproteins (HDL) by 36.14 %.
Conclusions. In animals with MS, changes in lipid metabolism were characterized by hyper- and dyslipidemia (statistically significantly higher levels of TC, TG, LDL on the background of the destruction of HDL) compared with controls.
References
Iqbal, J., Qarni, A.A., Hawwari, A., Alghanem, A.F., & Ahmed, G. (2018). Metabolic syndrome, dyslipidemia and regulation of lipoprotein metabolism. Current Diabetes Reviews, 14 (5), 427-433.
Babinets, L.S., Melnyk, N.A., & Shevchenko, N.O. (2018). Optimization of the complex therapy of chronic pancreatitis with metabolic syndrome. Wiadomosci Lekarskie, 71 (2), 337-340.
Grundy, S.M. (2016). Metabolic syndrome update. Trends in Cardiovascular Medicine, 26 (4), 364-373.
Dabke, K., Hendrick, G., & Devkota, S. (2019). The gut microbiome and metabolic syndrome. Journal of Clinical Investigation, 129 (10), 4050-4057.
Mumusoglu, S., & Yildiz, B.O. (2019). Metabolic syndrome during menopause. Current Vascular Pharmacology, 17 (6), 595-603.
Babinets, L.S., Меlnyk, N.A., Shevchenko, N.O., Migenko, B.O., Zaets, T.A. (2019). Kallikrein-kinin system disbalance in chronic pancreatis in combination with metabolic syndrome. Wiadomosci Lekarskie, 72 (11 cz 1), 2113-2126.
Weihe, P., & Weihrauch-Blüher S. (2019). Metabolic syndrome in children and adolescents: Diagnostic criteria, therapeutic options and perspectives. Current Obesity Reports, 8 (4), 472-479.
Tan, K.C. (2007). Management of dyslipidemia in the metabolic syndrome. Cardiovascular and Hematological Disorders – Drug Targets, 7 (2), 99-108.
(2019). Modeling of metabolic syndrome of different genesis in experimental animals (guidelines). State Institution “Institute of Endocrine Pathology. V.Ya. Danilevsky of the National Academy of Medical Sciences of Ukraine”. Kharkiv [in Ukrainian].
Grundy, S.M., Cleeman, J.I., & Daniels, S.R. (2005). Diagnosis and management of the metabolic syndrome. An American Heart Association. National Heart, Lung, and Blood Institute Scientific Statement: Executive Summary. Circulation, 112, e285-e290.
Markhon, N.O., Zhilyuk, V.I., Levykh, A.E., & Mamchur, V.Y. (2017). Features of changes in the lipid profile of the blood of rats in metabolic syndrome and pharmacotherapy with mountain ash fruit extract and resveratrol. Pharmacology and drug toxicology, 2 (53), 69-75 [in Ukrainian].
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2022 Medical and Clinical Chemistry
This work is licensed under a Creative Commons Attribution 4.0 International License.
